Department of Paediatric Oncology/Haematology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Department of Haematology/Oncology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Br J Haematol. 2019 Apr;185(2):266-283. doi: 10.1111/bjh.15770. Epub 2019 Feb 3.
Aneuploidy is common in paediatric B-cell precursor acute lymphoblastic leukaemia (ALL). Specific subgroups, such as high hyperdiploidy (>50 chromosomes or DNA Index ≥1·16) and hypodiploidy (<45 chromosomes), predict outcome of patients after primary treatment. Whether aneuploidy has a prognostic value for relapsed disease is yet to be determined. Using DNA index and centromere screening by multiplex ligation-dependent probe amplification, we investigated aneuploidy in 413 children treated for first relapse of B-cell precursor ALL according to the ALL-REZ BFM 2002 protocol. Ten-year event-free survival of patients with high hyperdiploid relapses approached 70%, whereas it was only 40% in low hyperdiploid relapses. Three patients with apparent hyperdiploid relapse had TP53 mutations. In these cases, array-based allelotyping revealed a hypodiploid origin with absence of the hypodiploid founder clone (masked hypodiploidy). Collectively, patients with evident or masked hypodiploid relapses showed an extremely low event-free survival rate of 9%. Importantly, the current relapse risk stratification did not identify cases with masked hypodiploidy as high-risk patients, due to their favourable clinical presentation. In multivariate analysis, hypodiploidy proved to be an independent prognostic factor. This finding supports stratification of relapses with hypodiploid origin into high-risk arms in future trials or allocation of patients to alternative treatment approaches.
非整倍体在儿科 B 细胞前体急性淋巴细胞白血病 (ALL) 中很常见。特定亚组,如高倍体性 (>50 条染色体或 DNA 指数≥1.16) 和低倍体性(<45 条染色体),可预测患者在初次治疗后的结局。非整倍体对复发疾病是否具有预后价值仍有待确定。我们使用 DNA 指数和多重连接依赖性探针扩增的着丝粒筛查,根据 ALL-REZ BFM 2002 方案,对 413 例接受 B 细胞前体 ALL 首次复发治疗的儿童进行了非整倍体研究。高倍体性复发患者的 10 年无事件生存率接近 70%,而低倍体性复发患者的生存率仅为 40%。3 例表现为明显高倍体性复发的患者存在 TP53 突变。在这些病例中,基于阵列的等位基因分析显示出低倍体起源,并缺乏低倍体起始克隆(隐匿性低倍体)。总的来说,明显或隐匿性低倍体性复发患者的无事件生存率极低,仅为 9%。重要的是,目前的复发风险分层并未将隐匿性低倍体性病例识别为高危患者,因为它们具有有利的临床表现。在多变量分析中,低倍体被证明是一个独立的预后因素。这一发现支持将起源于低倍体的复发病例分层为高危组,以便在未来的试验中进行分层,或为患者分配替代治疗方法。